dough(@semodough):$VKTX Baird who don’t even cover it -Viking making the case as potentially becoming the Least-Frequent Doser. Viking generated the biggest near-term excitement with maintenance data from the GLP-1/GIP receptor agonist, VK2735, which showed patients retained up to 97% of prior weight loss for 3 months on every-other-week dosing and up to 90% on monthly dosing for 3 months after an initial weekly-treatment period

dough

@semodough

BIOTECH man LONGTERM FOCUS many positions-also trade around my CORE holdings my opinion only do your own research with me

加入 September 2015

646 正在关注 44.4K 粉丝

dough@semodough

2026.09.26 19:44

$VKTX Baird who don’t even cover it -Viking making the case as potentially becoming the Least-Frequent Doser. Viking generated the biggest near-term excitement with maintenance data from the GLP-1/GIP receptor agonist, VK2735, which showed patients retained up to 97% of prior weight loss for 3 months on every-other-week dosing and up to 90% on monthly dosing for 3 months after an initial weekly-treatment period

显示更多